耐甲氧西林伪中间葡萄球菌危机:治疗犬最常见病原体的选择是否已经用尽?
耐甲氧西林伪中间葡萄球菌危机:治疗犬最常见病原体的选择是否已经用尽?
Douglas H. Pluta, MS,Jessica M. Gilbertie, DVM, PhD, MS*
关键词
- 伪中间葡萄球菌
- MRSP
- 抗菌药物耐药
- 抗菌药物管理
- 多重耐药
- 生物膜
- 新兴疗法
要点
- 伪中间葡萄球菌是犬脓皮病的主要细菌性病因,也是小动物实践中抗菌药物使用的主要驱动因素。
- MRSP作为临床重要的多重耐药病原体已在全球出现,流行率因地区、实践环境和患者人群而异。
- MRSP的临床影响由β-内酰胺类药物效力丧失、对其他抗菌药物类别频繁耐药、生物膜相关持续性和复发性疾病驱动。
- MRSP集中在慢性皮肤病患者、既往抗菌药物暴露、反复兽医就诊和反复感染的患者中,增加了临床负担和治疗复杂性。
- 新兴疗法可能有助于减少对常规全身抗菌药物的依赖,但需要临床验证。
引言
伪中间葡萄球菌是犬脓皮病的主要细菌病原体,也是小动物实践中最常遇到的细菌病原体之一。伪中间葡萄球菌是凝固酶阳性、革兰阳性球菌,属于中间葡萄球菌群(SIG),是一种共生菌和机会性病原体,主要适应犬,其次是猫,携带率从约37%到超过90%不等[1]。
在犬中,伪中间葡萄球菌是犬微生物培养中最常见的细菌[1],也是犬外耳炎、伤口感染、手术部位感染和尿路感染的常见原因[1]。犬脓皮病是犬就诊兽医护理的最常见原因之一,也是抗生素处方的最常见适应症[2]。
重要的是,许多伪中间葡萄球菌感染发生在慢性或复发性皮肤病患者中,导致反复抗菌药物暴露,使葡萄球菌脓皮病成为小动物实践中抗菌药物使用的主要驱动因素之一[3,4]。这种对抗菌药物的严重依赖产生了巨大的耐药选择压力,在过去20年中,耐甲氧西林伪中间葡萄球菌(MRSP)的出现和国际传播从根本上改变了治疗格局[5,6]。MRSP菌株经常表现出多重耐药和生物膜相关持续性,使感染更难治疗且更易复发[5,7]。
MRSP的出现已将伪中间葡萄球菌从常规临床病原体转变为重大抗菌药物耐药挑战。本综述总结了当前MRSP管理的流行病学、治疗局限性和新兴治疗策略。
耐甲氧西林伪中间葡萄球菌的出现和扩张
在过去20年中,MRSP已成为伴侣动物医学中的主要抗菌药物耐药(AMR)挑战[8]。现在全球都有报道,MRSP在许多兽医医院和转诊诊所中流行[5,8]。地理差异很大,在一些北美人群中,MRSP约占临床伪中间葡萄球菌分离株的30%至50%[6],而在欧洲人群中为5%至10%[9],在转诊和皮肤科人群中比率更高[9,10]。
甲氧西林耐药性通过获得mecA基因介导,该基因编码改变的青霉素结合蛋白PBP2a,并赋予对β-内酰胺类抗菌药物的耐药性[11]。MRSP谱系经常携带额外的耐药决定簇,导致多重耐药(MDR)[5,12-14]。在多项报告中,超过90%的MRSP分离株符合MDR标准[15-17],广泛耐药(XDR)分离株[14]现在已在多个地区出现,尽管泛耐药分离株仍然罕见[15]。即使在MRSP流行率较低的地方,频繁跨药物类别的交叉耐药也放大了临床影响。
除了AMR之外,许多伪中间葡萄球菌分离株可以形成生物膜[15,18],保护细菌免受宿主免疫防御并降低抗菌药物敏感性[7,19,20]。大多数来自犬皮肤感染的分离株在体外形成生物膜,表明生物膜相关耐受性在慢性或复发性感染中的作用[18,21]。
流行病学和疾病负担
伪中间葡萄球菌是犬皮肤和软组织感染的首要细菌病因,通常与脓皮病、外耳炎、伤口感染和术后感染有关[22,23]。大规模处方研究显示,皮肤病约占犬抗菌药物处方的20%至30%[4],脓皮病是最常提示治疗的诊断之一[24-26]。作为犬脓皮病的主要细菌病原体,伪中间葡萄球菌处于高疾病流行率和频繁抗菌药物暴露的交叉点。因此,MRSP的出现对慢性或复发性皮肤病患者产生了不成比例的影响,反复治疗周期放大了临床负担和抗菌药物选择压力[4,27,28]。
MRSP流行率因实践环境而异,初级保健中的报告率通常较低(10%-25%),低于转诊医院(15%-40%)[29]和皮肤科人群(40%-60%)[30]。这些差异反映了病例复杂性和转诊环境中慢性感染的集中[28,31]。重要的是,无论流行率如何,MRSP分离株经常是MDR,强化了它们在所有实践水平中的临床相关性[4]。
MRSP风险与既往抗菌药物暴露、慢性皮肤病和频繁医疗接触相关[27,32,33]。特应性皮炎、住院[21,27]、手术和反复兽医就诊通过破坏皮肤防御和创造反复治疗机会进一步增加风险[4,34]。因此,MRSP感染更有可能复发、经验性治疗失败,需要培养指导治疗[4,31]。定植动物也可以作为储存宿主,导致环境污染和医疗保健相关传播[8,35,36]。在兽医环境中,MRSP已从环境表面、设备和人员中分离出来。虽然人畜共患传播不如MRSA常见,但在与动物密切接触的个体中已有人类定植和感染的记录[37]。
当前治疗局限性
管理已转向以抗菌药物管理为重点的护理,强调细胞学、局部治疗、药敏指导治疗和基础疾病控制[4]。国际伴侣动物传染病学会(ISCAID)指南建议,在可行的情况下,表面和浅表脓皮病单独使用局部治疗,保留全身抗菌药物用于深部脓皮病或局部治疗无效或不切实际的病例[4,38,39]。当需要全身治疗时,培养和药敏试验越来越重要,特别是在反复感染、既往治疗失败、深部脓皮病、疑似MRSP或有大量既往抗菌药物暴露的患者中[40]。
MRSP最直接的治疗后果是β-内酰胺类药物作为可靠一线选择的丧失。由于mecA编码改变的青霉素结合蛋白PBP2a,MRSP对几乎所有β-内酰胺类抗菌药物都耐药[8],消除了用于犬脓皮病的关键药物,包括头孢氨苄和阿莫西林-克拉维酸[4,23]。替代口服选择——克林霉素、增效磺胺类、四环素类和氟喹诺酮类——在确认药敏时可能有用,但不能假定对MRSP有活性[3,9]。四环素类药敏性可变;氟喹诺酮类对特定感染仍然有用,但耐药性和管理限制了经验性使用[3]。
挽救性抗菌药物不能完全弥补这一治疗缺口[3,4]。氯霉素、利福平联合用药、利奈唑胺、万古霉素和替考拉宁可能对某些MRSP分离株保留活性,但安全性问题、监测要求、缺乏兽医断点和管理考虑限制了它们的常规使用[4,31]。至关重要的人类药物应避免使用,除非在专家监督下的特殊情况[4,41]。它们的使用不能弥补MDR和XDR伪中间葡萄球菌造成的治疗缺口。
局部治疗仍然是管理伪中间葡萄球菌感染的最重要工具之一,特别是对于脓皮病和外耳炎[4,38]。氯己定基洗发水、摩丝、湿巾、喷雾剂和冲洗液提供高局部防腐浓度,同时最小化全身暴露和选择压力[4,42]。然而,成功取决于病变可及性、产品选择、接触时间、应用频率、患者耐受性[38]和宠主依从性[39]。局部抗生素如莫匹罗星或夫西地酸可能对局灶性病变有用,但鉴于耐药风险和人类医学管理考虑,应限制使用[39]。
抗菌药物治疗单独在复发性疾病中很少足够。成功的管理需要识别和控制潜在驱动因素,如特应性皮炎、外寄生虫、内分泌病、角化障碍、解剖性皮肤皱褶、伤口、异物或其他屏障功能受损的原因[4,43]。不解决这些因素,治疗可能减少细菌负荷而不预防复发[44]。宠主依从性和现实的治疗计划同样重要,特别是当局部方案耗时或全身药物需要长期给药时[45]。在猫中,MRSP不太常见且研究较少,治疗同样受到药敏模式、药物耐受性和有限物种特异性数据的限制。
这些局限性强调了不断扩大的治疗缺口。虽然几种抗菌药物类别似乎可用,但很少有可预测的活性、安全、实用并有临床证据支持常规使用。局部治疗和基础疾病纠正仍然必不可少,但对所有患者来说不足,特别是那些深部、侵袭性或广泛耐药感染的患者。随着MDR和XDR伪中间葡萄球菌侵蚀常规治疗,迫切需要节省抗菌药物和辅助策略。
新兴治疗选择
MRSP和MDR伪中间葡萄球菌日益增长的流行率加强了对传统抗生素以外策略的兴趣。新兴方法包括新型小分子、噬菌体和内溶素、微生物组疗法、免疫调节、纳米材料、光动力疗法、疫苗和抗菌肽(AMPs)[5]。所有这些都有一个共同目标:改善耐药、复发和生物膜相关感染的管理,同时减少对常规抗菌药物的依赖。大多数仍处于临床前或早期转化阶段,在自然发生的犬疾病中的疗效数据有限[5,46,47]。
新型小分子和再利用药物——包括来自抗菌、抗寄生虫和农业管线的化合物——已显示出体外抗MRSP活性[48]。然而,大多数候选药物仍受到安全性、药代动力学和制剂不确定性的限制,在临床使用前需要大量的转化工作[49]。
噬菌体疗法很有吸引力,因为噬菌体可以选择性地靶向细菌病原体,同时保留周围微生物群[50,51]。几种噬菌体和噬菌体衍生酶显示出对MRSP和生物膜的活性,表明其用于难治性感染的效用[51,52]。然而,窄宿主范围、制剂挑战、监管不确定性、噬菌体耐药性出现和分离株特异性测试要求仍然是重要障碍[50,53]。
奥拉替尼和洛替维单抗提供了一个临床相关的宿主导向管理示例,可能通过改善屏障功能和减少自我创伤间接减少复发性脓皮病[54-56]。然而,这些疗法是否直接减少伪中间葡萄球菌定植、MRSP携带或脓皮病复发仍未得到测试[57]。未来的宿主导向方法可能靶向皮肤免疫、AMP产生和屏障功能,同时抑制促进细菌持续的炎症通路[58-61]。
疫苗接种将是复发性MRSP感染的有吸引力的策略,但目前没有许可疫苗,开发在很大程度上仍停留在概念阶段[1,44]。虽然粘附素、毒素和生物膜抗原已被提出作为靶点,但金黄色葡萄球菌疫苗项目的反复失败突显了识别葡萄球菌疾病保护性免疫反应的难度[62]。这些挑战可能与伪中间葡萄球菌特别相关,其中免疫逃避、抗原多样性和反复暴露可能使疫苗设计复杂化[1,63]。
纳米材料平台和光动力疗法已在实验中显示出抗葡萄球菌和抗生物膜活性,特别适用于局部皮肤、伤口和耳部感染[47]。纳米颗粒可以递送抗菌药物、破坏生物膜、产生活性氧或光热效应,或增强现有药物[64]。光动力方法使用光激活化合物在局部产生活性氧,靶向可及的皮肤、伤口或耳部感染[65]。这些平台可能通过多靶点机制起作用,不太容易受到经典耐药的影响。然而,对于伪中间葡萄球菌,这些方法在很大程度上仍处于临床前阶段,关于组织安全性、剂量、递送和自然疾病疗效仍有未解决的问题[47]。
基于微生物组的方法对于复发性伪中间葡萄球菌感染特别有吸引力,因为它们解决了脓皮病背后的破坏的皮肤生态系统[5,66,67]。在健康皮肤中,常驻微生物和先天防御产生定植抗性,限制机会性病原体。在犬脓皮病中,过敏性炎症、屏障功能障碍、抗菌药物暴露和菌群失调削弱了这种抗性,有利于伪中间葡萄球菌扩张[66,67]。人类金黄色葡萄球菌相关特应性皮炎表明这个生态系统可以被治疗性操纵,在一些研究中局部共生菌递送减少了病原体定植或疾病严重程度[68]。在伴侣动物中,基于微生物组的方法仍处于发现阶段——鉴定体外抑制MRSP的共生细菌,而不是证明活体生物治疗在自然疾病中的疗效[69]。
AMPs连接了微生物组恢复和靶向抗葡萄球菌治疗[70,71]。由上皮细胞、免疫细胞和微生物产生,AMPs通过与传统抗生素不同的机制杀死细菌,同时影响炎症、屏障修复和生物膜形成[71]。细菌素——细菌产生的肽类抗菌药物,用于与密切相关的生物竞争——在这方面特别相关[70,71]。因此,活体生物治疗、共生菌衍生细菌素和合成AMPs是恢复皮肤表面选择性抗菌压力的互补策略[68,70,72]。金黄色葡萄球菌系统的研究表明,共生菌衍生的AMPs可以减少病原体定植并重塑微生物群落,为伪中间葡萄球菌感染的类似方法提供了转化依据[70,72]。基于AMP的疗法仍处于早期开发阶段。临床转化需要证明对MRSP分离株和生物膜的活性,与局部或耳部制剂的兼容性,以及在复杂皮肤和耳部环境中的耐久性[1,71,73]。
挑战和未来方向
MRSP管理的核心挑战不仅仅是治疗耐药感染,而是预防复发和减少抗菌药物选择压力。有效的管理需要更早的风险识别、培养指导治疗、局部管理、感染控制和基础疾病纠正。
未来的进展需要改进监测、更快的诊断和更强的管理整合。同样重要的是解决复发的生物学驱动因素的策略:生物膜持续性、屏障功能障碍、菌群失调和定植抗性丧失。
新兴疗法提供了重要的前进道路,但需要在自然疾病中进行严格评估。最有希望的方法将补充而不是替代常规治疗,通过减少复发、保留抗菌药物效力和支持屏障和微生物组健康。临床研究应优先考虑与实践相关的结果:复发率、安全性、宠主可行性和管理影响。
临床护理要点
- 培养高风险病例,包括深部脓皮病、反复感染、既往治疗失败、疑似MRSP或需要全身抗菌药物治疗的病例。
- 在可行的情况下优先对表面和浅表脓皮病进行局部治疗,并选择宠主可以实际执行的方案。
- 选择性使用全身抗菌药物,根据药敏结果、感染深度、患者安全性、药物渗透性和管理原则选择药物;当怀疑或确认MRSP时避免使用β-内酰胺类药物。
- 通过控制基础疾病预防复发,包括过敏性皮炎、外寄生虫、内分泌病、角化障碍、皮肤皱褶、伤口、异物或其他屏障破坏病症。
- 通过抗菌药物管理、宠主教育、依从性计划、环境卫生和感染控制支持治疗成功,以减少复发和MRSP传播。
- 监测新兴疗法,但谨慎采用。新方法应符合适当的监管标准,并在常规使用前获得安全性、有效性、可行性和管理影响的可靠临床证据支持。
写作过程中AI和AI辅助技术的声明
在准备本作品期间,作者使用生成式AI协助查找相关参考文献并编辑内容以提高简洁性。所有参考文献都经过准确性审查,作者对出版物内容承担全部责任。
披露
Jessica M. Gilbertie博士是Qentoros, Inc.的首席科学官、联合创始人兼股权持有人,该公司是一家开发用于兽医应用的宿主防御肽疗法的生物技术公司。本综述的部分内容讨论了抗菌肽和相关新兴治疗策略,与该公司的研究兴趣重叠。作者力求对现有证据进行平衡的综述,包括这些方法的当前局限性和转化挑战。
参考文献
- Lynch SA, Helbig KJ. The complex diseases of Staphylococcus pseudintermedius in canines: where to next? Vet Sci 2021;8(1):11.
- Beaudoin AL, Bollig ER, Burgess BA, et al. Prevalence of antibiotic use for dogs and cats in United States veterinary teaching hospitals, August 2020. J Vet Intern Med 2023;37(5):1864.
- Papich MG, Papich MG. Antimicrobial agents in small animal dermatology for treating staphylococcal infections. J Am Vet Med Assoc 2023;261(S1):S130–9.
- Loeffler A, Cain CL, Ferrer L, et al. Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID). Vet Dermatol 2025;36(3):234.
- Nocera FP, De Martino L. Methicillin-resistant Staphylococcus pseudintermedius: epidemiological changes, antibiotic resistance, and alternative therapeutic strategies. Vet Res Commun 2024;48(6):3505–15.
- Sobkowich KE, Hui AY, Poljak Z, et al. Nationwide analysis of methicillin-resistant staphylococci in cats and dogs: resistance patterns and geographic distribution. Am J Vet Res 2025;86(3).
- Meroni G, Filipe JFS, Drago L, et al. Investigation on antibiotic-resistance, biofilm formation and virulence factors in multi drug resistant and non multi drug resistant Staphylococcus pseudintermedius. Microorganisms 2019;7(12):702.
- van Duijkeren E, Catry B, Greko C, et al. Review on methicillin-resistant Staphylococcus pseudintermedius. J Antimicrob Chemother 2011;66(12):2705–14.
- Feuer L, Frenzer SK, Merle R, et al. Comparative analysis of methicillin-resistant Staphylococcus pseudintermedius prevalence and resistance patterns in canine and feline clinical samples: insights from a three-year study in Germany. Antibiotics 2024;13(7):660.
- Scarpellini R, Cordovana M, Ambretti S, et al. Epidemiological multilevel surveillance of methicillin-resistant staphylococci in a veterinary teaching hospital and first characterization of Staphylococcus pseudintermedius isolates using IR biotyper®. Vet J 2025;314:106469.
- Krapf M, Muller E, Reissig A, et al. Molecular characterisation of methicillin-resistant Staphylococcus pseudintermedius from dogs and the description of their SCCmec elements. Vet Microbiol 2019;233:196–203.
- Kadlec K, Schwarz S. Antimicrobial resistance of Staphylococcus pseudintermedius. Vet Dermatol 2012;23(4).
- Giarratana LR, Pirolo M, Roch FF, et al. Evolving landscape of methicillin-resistant staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America. J Antimicrob Chemother 2025;81(1):dkaf340.
- Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infection 2012;18(3):268–81.
- Myrenas M, Pedersen K, Windahl U. Genomic analyses of methicillin-resistant Staphylococcus pseudintermedius from companion animals reveal changing clonal populations, multidrug resistance, and virulence. Antibiotics 2024;13(10).
- Worthing KA, Abraham S, Coombs GW, et al. Clonal diversity and geographic distribution of methicillin-resistant Staphylococcus pseudintermedius from Australian animals: discovery of novel sequence types. Vet Microbiol 2018;213:58–65.
- Wegener A, Broens EM, Zomer A, et al. Comparative genomics of phenotypic antimicrobial resistances in methicillin-resistant Staphylococcus pseudintermedius of canine origin. Vet Microbiol 2018;225:125–31.
- Casagrande Proietti P, Stefanetti V, Hyatt DR, et al. Phenotypic and genotypic characterization of canine pyoderma isolates of Staphylococcus pseudintermedius for biofilm formation. J Vet Med Sci 2015;77(8):945.
- Richter A, Fessler AT, Bottner A, et al. Reasons for antimicrobial treatment failures and predictive value of in-vitro susceptibility testing in veterinary practice: an overview. Vet Microbiol 2020;245:108694.
- Singh A, Walker M, Rousseau J, et al. Characterization of the biofilm forming ability of Staphylococcus pseudintermedius from dogs. BMC Vet Res 2013;9:93.
- Naziri Z, Majlesi M. Comparison of the prevalence, antibiotic resistance patterns, and biofilm formation ability of methicillin-resistant Staphylococcus pseudintermedius in healthy dogs and dogs with skin infections. Vet Res Commun 2023;47(2):713–21.
- Bannoehr J, Guardabassi L. Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet Dermatol 2012;23(4).
- Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis. Vet Dermatol 2014;25(3).
- Summers JF, Hendricks A, Brodbelt DC. Prescribing practices of primary-care veterinary practitioners in dogs diagnosed with bacterial pyoderma. BMC Vet Res 2014;10(1).
- Singleton DA, Sanchez-Vizcaino F, Dawson S, et al. Patterns of antimicrobial agent prescription in a sentinel population of canine and feline veterinary practices in the United Kingdom. Vet J 2017;224:18–24.
- Hardefeldt LY, Selinger J, Stevenson MA, et al. Population wide assessment of antimicrobial use in dogs and cats using a novel data source – a cohort study using pet insurance data. Vet Microbiol 2018;225:34–9.
- Wang Q, Chen S, Ma S, et al. Antimicrobial resistance and risk factors of canine bacterial skin infections. Pathogens 2025;14(4):14.
- Scott Weese J, Faires MC, Frank LA, et al. Factors associated with methicillin-resistant versus methicillin-susceptible Staphylococcus pseudintermedius infection in dogs. J Am Vet Med Assoc 2012;240(12):1450–5.
- Perkins AV, Sellon DC, Gay JM, et al. Prevalence of methicillin-resistant Staphylococcus pseudintermedius on hand-contact and animal-contact surfaces in companion animal community hospitals. Can Vet J 2020;61(6):613.
- Beck KM, Waisglass SE, Dick HLN, et al. Prevalence of meticillin-resistant Staphylococcus pseudintermedius (MRSP) from skin and carriage sites of dogs after treatment of their meticillin-resistant or meticillin-sensitive staphylococcal pyoderma. Vet Dermatol 2012;23(4):369-e67.
- Morris DO, Loeffler A, Davis MF, et al. Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures. Vet Dermatol 2017;28(3).
- Huerta B, Maldonado A, Ginel PJ, et al. Risk factors associated with the antimicrobial resistance of staphylococci in canine pyoderma. Vet Microbiol 2011;150(3–4):302–8.
- Lai CH, Ma YC, Shia WY, et al. Risk factors for antimicrobial resistance of staphylococcus species isolated from dogs with superficial pyoderma and their owners. Vet Sci 2022;9(7):9.
- Lehner G, Linek M, Bond R, et al. Case-control risk factor study of methicillin-resistant Staphylococcus pseudintermedius (MRSP) infection in dogs and cats in Germany. Vet Microbiol 2014;168(1):154–60.
- Davis MF, Iverson SA, Baron P, et al. Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci. Lancet Infect Dis 2012;12(9):703–16.
- Perkins AV, Sellon DC, Gay JM, et al. Longitudinal observation of meticillin-resistant Staphylococcus pseudintermedius pulsotypes in six veterinary hospitals in the north-western United States. Vet Rec Open 2022;9(1):e241.
- Moses IB, Santos FF, Gales AC. Human colonization and infection by staphylococcus pseudintermedius: an emerging and underestimated zoonotic pathogen. Microorganisms 2023;11(3):581.
- Santoro D, Santoro D. Topical therapy for canine pyoderma: what is new? J Am Vet Med Assoc 2023;261(S1):S140–8.
- Valentine B. Treating pyoderma without the use of systemic antibiotics. Can Vet J 2019;60(12):1361.
- Bajwa J. Canine superficial pyoderma and therapeutic considerations. Can Vet J 2016;57(2):204.
- Volkov S. WHO List of Medically Important Antimicrobials A risk management tool for mitigating antimicrobial resistance due to non-human use. 2024.
- Goldman G, Santoro D. In vitro evaluation of the antimicrobial activity of chlorhexidine alone or in combination with ketoconazole or miconazole against clinical isolates of Malassezia pachydermatis and multidrug-resistant Staphylococcus pseudintermedius. Microbiology (Read) 2026;172(4).
- Seckerdieck F, Mueller RS. Recurrent pyoderma and its underlying primary diseases: a retrospective evaluation of 157 dogs. Vet Rec 2018;182(15):434.
- Loeffler A, Lloyd DH. What has changed in canine pyoderma? A narrative review. Vet J 2018;235:73–82.
- Frosini SM, Loeffler A. Treating canine pyoderma with topical antibacterial therapy. Pract 2020;42(6):323–30.
- Mourenza A, Gil JA, Mateos LM, et al. Alternative anti-infective treatments to traditional antibiotherapy against staphylococcal veterinary pathogens. Antibiotics 2020;9(10):702.
- Stefanetti V, Passamonti F, Rampacci E. Antimicrobial strategies proposed for the treatment of S. pseudintermedius and other dermato-pathogenic staphylococcus spp. in companion animals: a narrative review. Vet Sci 2024;11(7):311.
- Edwards RL, Heueck I, Lee SG, et al. Potent, specific MEPicides for treatment of zoonotic staphylococci. PLoS Pathog 2020;16(6):e1007806.
- Pi H, Ogunniyi AD, Savaliya B, et al. Repurposing of the fasciolicide triclabendazole to treat infections caused by staphylococcus spp. and vancomycin-resistant enterococci. Microorganisms 2021;9(8):1697.
- Kortright KE, Chan BK, Koff JL, et al. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 2019;25(2):219–32.
- Moodley A, Kot W, Nalgaard S, et al. Isolation and characterization of bacteriophages active against methicillin-resistant Staphylococcus pseudintermedius. Res Vet Sci 2019;122:81–5.
- Nakamura T, Kitana J, Fujiki J, et al. Lytic activity of polyvalent staphylococcal bacteriophage PhiSA012 and its endolysin Lys-PhiSA012 against antibiotic-resistant staphylococcal clinical isolates from canine skin infection sites. Front Med 2020;7.
- Golban M, Charostad J, Kazemian H, et al. Phage-derived endolysins against resistant staphylococcus spp.: a review of features, antibacterial activities, and recent applications. Infect Dis Ther 2025;14(1):13–57.
- Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013;24(5).
- Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 2016;27(6):505-e136.
- Moyaert H, Van Brussel L, Borowski S, et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017;28(6):593-e145.
- Rynhoud H, Croton C, Henry G, et al. The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study. BMC Vet Res 2022;18(1):151.
- Hata TR, Gallo RL. Antimicrobial peptides, skin infections and atopic dermatitis. Semin Cutan Med Surg 2008;27(2):144.
- Nakatsuji T, Brinton SL, Cavagnero KJ, et al. Competition between skin antimicrobial peptides and commensal bacteria in type 2 inflammation enables survival of S. aureus. Cell Rep 2023;42(5):112494.
- Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol 2020;140(1):191–202.e7.
- Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Investig 2010;120(5):1762–73.
- Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012;2:16.
- Tsai CM, Caldera JR, Hajam IA, et al. Non-protective immune imprint underlies failure of Staphylococcus aureus IsdB vaccine. Cell Host Microbe 2022;30(8):1163–72.e6.
- Xie Y, Liu H, Teng Z, et al. Nanomaterial-enabled anti-biofilm strategies: new opportunities for treatment of bacterial infections. Nanoscale 2025;17(10):5605–28.
- Hu X, Huang YY, Wang Y, et al. Antimicrobial photodynamic therapy to control clinically relevant biofilm infections. Front Microbiol 2018;9(JUN):377371.
- Bradley CW, Morris DO, Rankin SC, et al. Longitudinal evaluation of the skin microbiome and association with microenvironment and treatment in canine atopic dermatitis. J Invest Dermatol 2016;136(6):1182.
- Santoro D, Saridomichelakis M, Eisenschenk M, et al. Update on the skin barrier, cutaneous microbiome and host defence peptides in canine atopic dermatitis. Vet Dermatol 2024;35(1):5–14.
- Nakatsuji T, Hata TR, Tong Y, et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat Med 2021;27(4).
- O'Neill AM, Worthing KA, Kulkarni N, et al. Antimicrobials from a feline commensal bacterium inhibit skin infection by drug-resistant S. pseudintermedius. eLife 2021;10:e66793.
- Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med 2017;9(378):eaah4680.
- Pfalzgraff A, Brandenburg K, Weindl G. Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol 2018;9(MAR):281.
- Torres Salazar BO, Dema T, Schilling NA, et al. Commensal production of a broad-spectrum and short-lived antimicrobial peptide polyene eliminates nasal Staphylococcus aureus. Nat Microbiol 2023;9(1):200–13.
- Luo Y, Song Y. Mechanism of antimicrobial peptides: antimicrobial, anti-inflammatory and antibiofilm activities. Int J Mol Sci 2021;22(21):11401.